These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 4066221)

  • 1. Homoharringtonine: a phase I evaluation.
    Stewart JA; Krakoff IH
    Invest New Drugs; 1985; 3(3):279-86. PubMed ID: 4066221
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I clinical investigation of homoharringtonine.
    Legha SS; Keating M; Picket S; Ajani JA; Ewer M; Bodey GP
    Cancer Treat Rep; 1984 Sep; 68(9):1085-91. PubMed ID: 6478448
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I trial of homoharringtonine administered by prolonged continuous infusion.
    Neidhart JA; Young DC; Kraut E; Howinstein B; Metz EN
    Cancer Res; 1986 Feb; 46(2):967-9. PubMed ID: 3940656
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Homoharringtonine: an effective new drug for remission induction in refractory nonlymphoblastic leukemia.
    Warrell RP; Coonley CJ; Gee TS
    J Clin Oncol; 1985 May; 3(5):617-21. PubMed ID: 3889229
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I trial of homoharringtonine.
    Neidhart JA; Young DC; Derocher D; Metz EN
    Cancer Treat Rep; 1983 Sep; 67(9):801-4. PubMed ID: 6883357
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I trial of homoharringtonine administered as a 5-day continuous infusion.
    Coonley CJ; Warrell RP; Young CW
    Cancer Treat Rep; 1983; 67(7-8):693-6. PubMed ID: 6871884
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of homoharringtonine efficacy in the treatment of squamous cell carcinoma of the head and neck: a phase II Illinois Cancer Council Study.
    Runge-Morris MA; Kies MS; Vokes E; Blough R; Weidner L; Knop R; Rowland K
    Invest New Drugs; 1989 Jul; 7(2-3):269-73. PubMed ID: 2793384
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II study of low-dose continuous infusion homoharringtonine in refractory acute myelogenous leukemia.
    Kantarjian HM; Keating MJ; Walters RS; Koller CA; McCredie KB; Freireich EJ
    Cancer; 1989 Mar; 63(5):813-7. PubMed ID: 2914287
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II studies of homoharringtonine in patients with advanced malignant melanoma; sarcoma; and head and neck, breast, and colorectal carcinomas.
    Ajani JA; Dimery I; Chawla SP; Pinnamaneni K; Benjamin RS; Legha SS; Krakoff IH
    Cancer Treat Rep; 1986 Mar; 70(3):375-9. PubMed ID: 3955548
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Continuous infusion homoharringtonine (NSC 141633) in refractory acute nonlymphocytic leukemia. An ECOG pilot study.
    Stewart JA; Cassileth PA; Bennett JM; O'Connell MJ
    Am J Clin Oncol; 1988 Dec; 11(6):627-9. PubMed ID: 3189228
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II study of homoharringtonine in patients with recurrent primary malignant central nervous system tumors.
    Feun LG; Savaraj N; Landy H; Levin H; Lampidis T
    J Neurooncol; 1990 Oct; 9(2):159-63. PubMed ID: 2175770
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I trial of homoharringtonine in children with refractory leukemia.
    Tan CT; Luks E; Bacha DM; Steinherz P; Steinherz L; Mondora A
    Cancer Treat Rep; 1987 Dec; 71(12):1245-8. PubMed ID: 3480043
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New natural products in cancer chemotherapy.
    Slichenmyer WJ; Von Hoff DD
    J Clin Pharmacol; 1990 Sep; 30(9):770-88. PubMed ID: 1980498
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intermittent Iv homoharringtonine for the treatment of refractory epithelial carcinoma of the ovary: a phase II trial.
    Kavanagh JJ; Gershenson DM; Copeland LJ; Wharton JT; Rutledge FN; Krakoff IH
    Cancer Treat Rep; 1984 Dec; 68(12):1503-4. PubMed ID: 6542450
    [No Abstract]   [Full Text] [Related]  

  • 15. Cephalotaxine esters: antileukemic advance or therapeutic failure?
    Grem JL; Cheson BD; King SA; Leyland-Jones B; Suffness M
    J Natl Cancer Inst; 1988 Sep; 80(14):1095-103. PubMed ID: 3045335
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of low-dose cytarabine, homoharringtonine and granulocyte colony-stimulating factor priming regimen on patients with advanced myelodysplastic syndrome or acute myeloid leukemia transformed from myelodysplastic syndrome.
    Wu L; Li X; Su J; Chang C; He Q; Zhang X; Xu L; Song L; Pu Q
    Leuk Lymphoma; 2009 Sep; 50(9):1461-7. PubMed ID: 19672772
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Homoharringtonine as a new antileukemic agent.
    Ohnuma T; Holland JF
    J Clin Oncol; 1985 May; 3(5):604-6. PubMed ID: 3889228
    [No Abstract]   [Full Text] [Related]  

  • 18. A phase II trial of homoharringtonine and caracemide in the treatment of patients with advanced large bowel cancer.
    Witte RS; Lipsitz S; Goodman TL; Asbury RF; Wilding G; Strnad CM; Smith TJ; Haller DG
    Invest New Drugs; 1999; 17(2):173-7. PubMed ID: 10638488
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Homoharringtonine in patients with myelodysplastic syndrome (MDS) and MDS evolving to acute myeloid leukemia.
    Feldman EJ; Seiter KP; Ahmed T; Baskind P; Arlin ZA
    Leukemia; 1996 Jan; 10(1):40-2. PubMed ID: 8558935
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Homoharringtonine in combination with cytarabine for patients with acute myelogenous leukemia.
    Feldman E; Arlin Z; Ahmed T; Mittelman A; Puccio C; Chun H; Cook P; Baskind P
    Leukemia; 1992 Nov; 6(11):1189-91. PubMed ID: 1434803
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.